For the Inventor, By the Inventor

Enter assignee name

Baltimore, MD, United States of America

Agenebio, Inc.

USPTO Granted Patents = 14

% Expired Patents = 21.4

CIPO Patents = 2

EPO Patents = 8

Forward Citations = 47

Loading Chart...

Loading Chart...

14 inventors (with patents filed for the assignee):

Belew Mekonnen (9 out of 10 patents)

Jianxing Huang (9 out of 12 patents)

John Anthony Butera (9 out of 58 patents)

4. Hemantbhai Patel (4 out of 7 patents)

5. Qin Jiang (2 out of 15 patents)

6. Robert Jason Herr (2 out of 19 patents)

7. Emily Elizabeth Freeman (2 out of 24 patents)

8. Nicholas James Mayhew (2 out of 5 patents)

9. Michela Gallagher (2 out of 7 patents)

10. Elsie Melsopp (2 out of 2 patents)

11. Jack Lawrence James (2 out of 4 patents)

12. Sharon J Rosenzweig-Lipson (2 out of 15 patents)

13. John Adams Lowe, Iii (2 out of 83 patents)

14. Gardiner Smith (1 out of 1 patent)

15. Sharon Rosenzweig-Lipson (0 patent)

14 patents: Sort by Forward Citations

1. 12528819 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2026-01-20),

2. 12291535 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2025-05-06),

3. 12024525 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2024-07-02),

4. 11505555 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2022-11-22),

5. 11414425 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2022-08-16),

6. 11312721 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2022-04-26),

7. 11160785 - Methods and compositions for improving cognitive function (2021-11-02),

8. 11142529 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2021-10-12),

9. 10925834 - Extended release pharmaceutical compositions of levetiracetam (2021-02-23),

10. 10815242 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2020-10-27),

11. 10329301 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2019-06-25),

12. 10159648 - Extended release pharmaceutical compositions of levetiracetam (2018-12-25),

13. 9801879 - Pyridazine derivatives, compositions and methods for treating cognitive impairment (2017-10-31),

14. 9145372 - Pyridazine derivatives, compositions and methods for treating cognitive impairment (2015-09-29),

AGENEBIO, INC. is a biotechnology company focused on developing innovative therapies for Alzheimer's disease and other neurodegenerative diseases. Their mission is to improve the lives of patients suffering from these devastating conditions by discovering and developing breakthrough treatments. With a team of dedicated scientists and clinicians, AGENEBIO is at the forefront of research and development to address the urgent need for effective therapies in the field of neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

14 Patents

#35 in Baltimore, MD

#305 in Maryland

#22,289 in US

#42,168 in the World

Baltimore, MD, United States of America

Agenebio, Inc.

Forward Citations = 47

14 inventors:

Belew Mekonnen (9 out of 10 patents)

Jianxing Huang (9 out of 12 patents)

John Anthony Butera (9 out of 58 patents)

4. Hemantbhai Patel (4 out of 7 patents)

5. Qin Jiang (2 out of 15 patents)

Please report any incorrect information to [email protected]

Loading…